{"title":"重组腺病毒基因治疗的展望。","authors":"W Siegfried","doi":"10.1055/s-0029-1211201","DOIUrl":null,"url":null,"abstract":"The cure of inherited disease in man at the genetic level is a dream of modern medicine that becomes closer every day with the development of more precise and faster methods in molecular biology. Already this year, we can expect the first experimental therapy with recombinant adenoviruses in individuals suffering from cystic fibrosis (CF), after the NIH Recombinant DNA Advisory Committee (RAC), in December 1992, gave full approvai to begin treating humans.","PeriodicalId":12104,"journal":{"name":"Experimental and clinical endocrinology","volume":"101 1","pages":"7-11"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0029-1211201","citationCount":"23","resultStr":"{\"title\":\"Perspectives in gene therapy with recombinant adenoviruses.\",\"authors\":\"W Siegfried\",\"doi\":\"10.1055/s-0029-1211201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The cure of inherited disease in man at the genetic level is a dream of modern medicine that becomes closer every day with the development of more precise and faster methods in molecular biology. Already this year, we can expect the first experimental therapy with recombinant adenoviruses in individuals suffering from cystic fibrosis (CF), after the NIH Recombinant DNA Advisory Committee (RAC), in December 1992, gave full approvai to begin treating humans.\",\"PeriodicalId\":12104,\"journal\":{\"name\":\"Experimental and clinical endocrinology\",\"volume\":\"101 1\",\"pages\":\"7-11\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1993-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1055/s-0029-1211201\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0029-1211201\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0029-1211201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Perspectives in gene therapy with recombinant adenoviruses.
The cure of inherited disease in man at the genetic level is a dream of modern medicine that becomes closer every day with the development of more precise and faster methods in molecular biology. Already this year, we can expect the first experimental therapy with recombinant adenoviruses in individuals suffering from cystic fibrosis (CF), after the NIH Recombinant DNA Advisory Committee (RAC), in December 1992, gave full approvai to begin treating humans.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
